Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and ...
Its biggest competitor is GSK, which also has a new dual bronchodilator Anoro Ellipta. Results from GSK's combination have underwhelmed until now, and failed to show superiority to the older ...
Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and critical care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback